This article is part of a Chronicle. See more from this Chronicle
Sean-Paul Brankin, Nov 12, 2008
One reaction to the pharmaceuticals sector inquiry, particularly from the originator side of the industry, has been to question the need for the investigation. What is certain is that the Commission has set itself a challenging task. It has chosen to investigate a number of competition law issues that are likely to pose substantial legal and evidential difficulties. However, the sector, and originators in particular, cannot afford to be complacent. Information already in the public domain suggests that the industry probably should not expect to be given a clean bill of health.
